An attempt to use a common staging system in rhabdomyosarcoma: A report of an international workshop initiated by the international society of pediatric oncology (SIOP)-Reference-Cited by-同舟云学术

An attempt to use a common staging system in rhabdomyosarcoma: A report of an international workshop initiated by the international society of pediatric oncology (SIOP)

Published:1989 Issue:3 Volume:17 Page:210-215
ISSN:0098-1532
Container-title:Medical and Pediatric Oncology
language:en
Short-container-title:Med. Pediatr. Oncol.

Author:

Rodary C.,Flamant F.,Donaldson S. S.,

Publisher

Wiley

Subject

Cancer Research,Oncology,Pediatrics, Perinatology and Child Health

Reference10 articles.

1. Incidence of malignant tumors in U.S. children

2. (ed): “TNM Classification of Pediatric Tumours.” Geneva: UICC (Union Internationale Contre le Cancer), pp 23–28, 1982.

3. Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II).

4. Childhood rhabdomyosarcoma: Experience of the Children's Solid Tumour Group

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study);ESMO Open;2024-05

2. Reappraisal of prognostic factors used in the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 study for localized rhabdomyosarcoma to optimize risk stratification and generate a prognostic nomogram;Cancer;2024-02-24

3. Non‑syndromic first case of pediatric rhabdomyosarcoma originating from the umbilical left medial ligament: A case report;Oncology Letters;2023-12-01

4. Larotrectinib versus historical standard of care in patients with infantile fibrosarcoma: protocol of EPI-VITRAKVI;Future Oncology;2023-08

5. Clinical characteristics and outcomes for children, adolescents and young adults with “CIC‐fused” or “BCOR‐rearranged” soft tissue sarcomas: A multi‐institutional European retrospective analysis;Cancer Medicine;2023-05-22